证券之星消息，1月22日医疗服务板块较上一交易日下跌0.25%，诚达药业领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688710 | 益诺思 | 66.35 | 5.96% | | 1.44万 | 9269.41万 | | 300683 | 海特生物 | 30.94 | 4.28% | | 12.00万 | - 3.60亿 | | 301239 | 普瑞眼科 | 34.79 | 3.73% | | 2.24万 | 7657.97万 | | 000710 | 贝瑞基因 | 12.94 | 2.21% | | 14.77万 | 2006T | | 002173 | 创新医疗 | 28.93 | 1.97% | | 45.44万 | 13.10亿 | | 600568 | ST中珠 | 2.69 | 1.89% | | 35.10万 | 9428.7 ...

证券之星消息，1月21日医疗服务板块较上一交易日上涨0.18%，南模生物领涨。当日上证指数报收于 4116.94，上涨0.08%。深证成指报收于14255.12，上涨0.7%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流入5050.97万元，游资资金净流入3.24亿元，散户资 金净流出3.75亿元。医疗服务板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 49.79 | 7.01% | 2.00万 | i 9802.06万 | | 300683 | 海特生物 | 29.67 | 5.74% | 10.78万 | 3.22 Z | | 300244 | 迪安诊断 | 26.46 | 5.59% | 79.63万 | 21.30亿 | | 600568 | ST中珠 | 2.64 | 5.18% | 37.65万 | 9806.43万 | | 600763 | 通策医疗 | 46.51 | 4.99% | 19. ...

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院医药研发外包(CRO)研究小组发布的《中国医药研发外包（CRO）行 业市场前瞻与投资战略规划分析报告》。 行业主要上市公司：目前国内CRO行业主要的上市公司有药明康德(603259.SH)、康龙化成(300759.SZ)、泰 格医药(300347.SZ)、凯莱英(002821.SZ)、昭衍新药(603127.SH)、九洲药业(603456.SH)、皓元医药 (688131.SH)、博腾股份(300363.SZ)、成都先导(688222.SH)、药石科技(300725.SZ)等。 本文核心数据：CRO产业市场规模 行业概况 2、CRO行业产业链剖析 中国 CRO 产业链贯穿药品全生命周期，可以分为三个阶段。研发阶段CRO，含临床前药物发现、化合物合 成等基础研发与临床阶段试验等;生产阶段CMO/CDMO，覆盖化学原料药、生物药、化学药制剂等不同类型 药物的生产环节;销售阶段CSO，以渠道管理为核心，配套推广营销与市场监测，服务企业、科研机构、医 1、CRO的定义 合同研究组织 (Contract Research Organization, CRO) 是指 ...

Group 1 - The core viewpoint of the news is that the Medical ETF (512170) has experienced a decline of 1.61%, with the latest price at 0.366 yuan and a turnover rate of 2.25% [1] - The Medical ETF closely tracks the CSI Medical Index, which includes companies involved in medical devices, medical services, and medical information technology [1] - The latest scale of the Medical ETF is 26.117 billion yuan, with a total of 70.245 billion shares, indicating an increase of 524 million yuan in fund size over the past month [1] Group 2 - As of the previous trading day, the Medical ETF (512170) saw a net inflow of 26.1418 million yuan [2] - The top ten weighted stocks in the CSI Medical Index include WuXi AppTec, Mindray Medical, United Imaging Healthcare, Aier Eye Hospital, Kanglong Chemical, Tigermed, Lepu Medical, Yuyue Medical, New Industry, and Meinian Onehealth [2]

Group 1 - The core viewpoint of the articles indicates a mixed performance in the medical and healthcare sector, with the China Medical and Medical Device Innovation Index experiencing a decline of 0.85% as of January 20, 2026, while certain stocks like Xinhecheng and Xingqi Eye Medicine showed gains [1] - The medical innovation ETF saw a decrease of 0.80%, with the latest price at 0.37 yuan, reflecting the overall market sentiment [1] - The brain-computer interface concept is gaining traction, supported by a significant investment of over 730 billion yuan in technology loans by the China Export-Import Bank, focusing on AI, brain-computer interfaces, humanoid robots, and high-end instruments [1] Group 2 - According to J.P. Morgan's conference, over 20 Chinese companies participated, highlighting the growing global interest in domestic innovative drugs and medical devices, which is expected to boost industry sentiment [1] - The China Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, with the top ten stocks accounting for 63.75% of the index [2] - Recent data shows a net inflow of 1.8727 million yuan into the medical innovation ETF, with a total of 59.7643 million yuan over the past five trading days, indicating a positive trend in investor interest [2]

Core Viewpoint - The Hong Kong capital market has seen a significant increase in refinancing activities at the beginning of 2026, with over HKD 27 billion raised, marking a more than 20-fold increase compared to the same period in 2025, setting a vibrant tone for the year ahead [1][3]. Group 1: Active Refinancing at the Start of 2026 - As of January 18, 2026, Hong Kong-listed companies have raised over HKD 27 billion through various methods such as placements and rights issues, compared to HKD 1.1 billion in the same period of 2025 [1][3]. - The robust refinancing activity is built on the historical high of HKD 325.32 billion in 2025, which surpassed the IPO fundraising scale for the first time [3]. - Major companies like BYD and Xiaomi have completed significant fundraising projects, contributing to a trend of continuous capital replenishment [3]. Group 2: Structural Characteristics of Refinancing - The refinancing activities in early 2026 are characterized by a diverse industry distribution, including sectors like oil and gas, construction, software services, and healthcare [7]. - Notable companies such as SF Express and Jitu Express have raised over HKD 1 billion, indicating a clear differentiation in fundraising scales [7]. - The use of raised funds is closely aligned with core business strategies, including international expansion, technology R&D, and financial structure optimization [7]. Group 3: Advantages of Hong Kong's Refinancing Market - The efficiency of Hong Kong's refinancing system allows companies to quickly seize market opportunities without prior regulatory approval for placements [4]. - The flexible and diverse financing tools available in the Hong Kong market cater to various corporate needs, enhancing the ability to raise funds [5]. - The market's recovery and valuation improvements since Q3 2024 have created a favorable environment for refinancing activities [5]. Group 4: Emerging Trends in Refinancing - The refinancing landscape is evolving, with a notable increase in strategic mutual holdings among companies, exemplified by the collaboration between SF Express and Jitu Express [8]. - The current refinancing structure shows a higher proportion of traditional and consumer industries compared to emerging sectors, highlighting the complementary nature of Hong Kong and A-share markets [8]. - Future trends indicate that refinancing will remain high but with a more stable growth rate, and the focus will shift towards optimizing capital structures and enhancing R&D capabilities [10].

Group 1 - The core viewpoint of the article highlights that 康龙化成 (Crown Bioscience) is experiencing a decline in stock price, dropping over 3% to HKD 22.12, with a trading volume of HKD 113 million [2] - On January 15, 康龙化成 announced a plan to place nearly 58.44 million new H-shares at a price of HKD 22.82 per share, representing an approximate 8.5% discount to the closing price on January 14, aiming to raise a net amount of about HKD 1.319 billion [2] - Approximately 70% of the funds raised will be allocated to project construction to enhance laboratory service facilities, drug process development, and production capacity [2] Group 2 - 康龙化成 recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between HKD 1.614 billion and HKD 1.686 billion, reflecting a decrease of 6% to 10% compared to the previous year [2] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16%, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [2]

每经AI快讯，康龙化成(03759.HK)再跌超3%，截至发稿跌3.41%，报22.12港元，成交额1.13亿港元。 ...

Core Viewpoint - Kanglong Chemical (03759) has seen a decline of over 3%, currently trading at HKD 22.12, with a transaction volume of HKD 113 million [1] Group 1: Fundraising and Stock Issuance - On January 15, Kanglong Chemical announced a plan to issue nearly 58.44 million new H-shares at a price of HKD 22.82 per share, representing a discount of approximately 8.5% compared to the closing price on January 14 [1] - The net proceeds from this fundraising are expected to be around HKD 1.319 billion, with approximately 70% allocated for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] Group 2: Earnings Forecast - Kanglong Chemical recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between HKD 1.614 billion and HKD 1.686 billion, indicating a year-on-year decline of 6% to 10% [1] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16%, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [1]

消息面上，1月15日，康龙化成发布公告，拟配售近5844.08万股新H股，配售价每股22.82港元，较1月 14日收市价折让约8.5%，募资所得款项净额约13.19亿港元，其中约70%将用于公司的项目建设，以加 强实验室服务设施、药物工艺开发及生产设施的能力及产能。 康龙化成（300759）(03759)再跌超3%，截至发稿，跌3.41%，报22.12港元，成交额1.13亿港元。 此外，康龙化成近日公布业绩预告，预计2025年归属于上市公司股东的净利润为16.14亿元-16.86亿元， 比上年同期下降6%-10%。报告期内，公司营业收入同比增长13%-16%，扣除非经常性损益后的净利润 同比增长36%-41%。 ...